This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pathak, M. K. Articles by Yi, T. Search for Related Content PubMed PubMed Citation Articles by Pathak, M. K. Articles by Yi, T.

Department of Cancer Biology, Lerner Research Institute [M. K. P., D. D., E. C. B., T. Y.], Taussig Cancer Center [D. J. L., E. C. B., T. Y.], and Department of Pathology [C. F.], The Cleveland Clinic Foundation, Cleveland, Ohio 44195

The PRL family oncogenic phosphatases are attractive targets for developing inhibitors as anticancer therapeutics given their potentially pathogenic role in human malignancies. Herein we demonstrate that pentamidine, an anti-protozoa drug with an unknown mechanism of action, is an inhibitor of PRLs with anticancer potential. Pentamidine at its therapeutic doses inhibited recombinant PRL phosphatases in vitro and inactivated ectopically expressed PRLs in NIH3T3 transfectants with an effective duration more than 24 h after a pulse cell treatment. The drug had in vitro growth-inhibitory activity against human cancer cell lines that express the endogenous PRLs. Pentamidine at a tolerable dose markedly inhibited the growth of WM9 human melanoma tumors in nude mice coincident with the induction of tumor cell necrosis and is capable of inactivating ectopically expressed PRL-2 in the cancer cells. These observations suggest the potential of pentamidine in anticancer therapies and may provide a basis for developing novel PTPase-targeted therapeutics.

This article has been cited by other articles:

				M. S. Lee, L. Johansen, Y. Zhang, A. Wilson, M. Keegan, W. Avery, P. Elliott, A. A. Borisy, and C. T. Keith The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action Cancer Res., December 1, 2007; 67(23): 11359 - 11367. [Abstract] [Full Text] [PDF]

				J. S. Lazo, J. J. Skoko, S. Werner, B. Mitasev, A. Bakan, F. Koizumi, A. Yellow-Duke, I. Bahar, and K. M. Brummond Structurally Unique Inhibitors of Human Mitogen-Activated Protein Kinase Phosphatase-1 Identified in a Pyrrole Carboxamide Library J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 940 - 947. [Abstract] [Full Text] [PDF]

				Y. A. Kuryshev, L. Wang, B. A. Wible, X. Wan, and E. Ficker Antimony-Based Antileishmanial Compounds Prolong the Cardiac Action Potential by an Increase in Cardiac Calcium Currents Mol. Pharmacol., April 1, 2006; 69(4): 1216 - 1225. [Abstract] [Full Text] [PDF]

				C. Rouleau, A. Roy, T. St. Martin, M. R. Dufault, P. Boutin, D. Liu, M. Zhang, K. Puorro-Radzwill, L. Rulli, D. Reczek, et al. Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol. Cancer Ther., February 1, 2006; 5(2): 219 - 229. [Abstract] [Full Text] [PDF]

				B. J. Stephens, H. Han, V. Gokhale, and D. D. Von Hoff PRL phosphatases as potential molecular targets in cancer Mol. Cancer Ther., November 1, 2005; 4(11): 1653 - 1661. [Abstract] [Full Text] [PDF]

				I. C. Cuevas, P. Rohloff, D. O. Sanchez, and R. Docampo Characterization of Farnesylated Protein Tyrosine Phosphatase TcPRL-1 from Trypanosoma cruzi Eukaryot. Cell, September 1, 2005; 4(9): 1550 - 1561. [Abstract] [Full Text] [PDF]

				Y. A. Kuryshev, E. Ficker, L. Wang, P. Hawryluk, A. T. Dennis, B. A. Wible, A. M. Brown, J. Kang, X.-L. Chen, K. Sawamura, et al. Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 316 - 323. [Abstract] [Full Text] [PDF]

				T. Y-K. Chow, M. A. Alaoui-Jamali, C. Yeh, L. Yuen, and D. Griller The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer Mol. Cancer Ther., August 1, 2004; 3(8): 911 - 920. [Abstract] [Full Text] [PDF]